sb 216763 has been researched along with Lung Injury, Acute in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abraham, E; Inoki, K; Jiang, S; Liu, Y; Park, DW; Siegal, GP; Zmijewski, JW | 1 |
1 other study(ies) available for sb 216763 and Lung Injury, Acute
Article | Year |
---|---|
GSK3β-dependent inhibition of AMPK potentiates activation of neutrophils and macrophages and enhances severity of acute lung injury.
Topics: Acute Lung Injury; AMP-Activated Protein Kinases; Animals; Cell Line; Chemokine CXCL2; Chromones; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HMGB1 Protein; I-kappa B Kinase; Indoles; Lipopolysaccharides; Macrophage Activation; Macrophages; Maleimides; Mice; Morpholines; Neutrophil Activation; Neutrophils; Phosphorylation; Pulmonary Edema; Tumor Necrosis Factor-alpha | 2014 |